The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses four-year folllow-up results of a Phase II study of obinutuzumab, ibrutinib, and venetoclax in patients with chronic lymphocytic leukemia (CLL). At extended follow-up, remissions remain durable after fixed duration obinutuzumab, ibrutinib, and venetoclax. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
